Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.69 |
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | GSK3A | P49840 | 2/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.65 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | KRAS | P01116 | 5/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28398120 | 0.93 | HINT1 (0.70) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL1034011 | 0.92 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL30396629 | 0.89 | HINT1 (0.66) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL9231860 | 0.89 | HINT1 (0.71) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.89 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.89 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.89 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL30567341 | 0.88 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.88 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2014087 | 0.88 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1831 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086717-A2 | HETEROARYL ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024086705-A2 | BICYCLIC ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-25 | — | — | WO | claimed |
| CN-108473969-B | Modification of RNA-associated enzymes for enhanced production | 川斯勒佰尔公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114686548-A | Modification of RNA-associated enzymes for enhanced production | 川斯勒佰尔公司 | 2022-07-01 | — | — | CN | claimed |
| EP-3994468-A1 | METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS | Oxford University Innovation Limited (GB) | 2022-05-11 | — | — | EP | claimed |
| EP-3497445-B1 | METHODS FOR MICROPATTERNING AND MICROPATTERNED DEVICES | IST AUSTRIA INSTITUTE OF SCIENCE AND TECH AUSTRIA (AT) | 2022-02-16 | — | — | EP | claimed |
| EP-3878955-A1 | MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION | Translate Bio, Inc. (US) | 2021-09-15 | — | — | EP | claimed |
| EP-3362555-B1 | MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION | TRANSLATE BIO INC (US) | 2021-01-13 | — | — | EP | claimed |
| WO-2021001665-A1 | METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-01-07 | — | — | WO | claimed |
| US-20190234956-A1 | METHOD FOR DETECTING CROSSLINKED PEPTIDES VIA REPRODUCIBLE FRAGMENTATION IN A MASS SPECTROMETER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2019-08-01 | — | — | US | claimed |
| US-20040156852-A1 | Therapy via targeted delivery of nanoscale particles | TRITON BIOSYSTEMS, INC. (US) | 2004-08-12 | — | — | US | claimed |
| US-20040146858-A1 | Novel siRNA gene libraries and methods for their production and use | IMMUSOL, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004009794-A2 | NOVEL siRNA LIBRARIES AND THEIR PRODUCTION AND USE | IMMUSOL, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1268854-A4 | HIGH SPECIFICITY MARKER DETECTION | UNIV JEFFERSON (US) | 2003-05-02 | — | — | EP | claimed |
| EP-1268854-A1 | HIGH SPECIFICITY MARKER DETECTION | Thomas Jefferson University (US) | 2003-01-02 | — | — | EP | claimed |
| US-20020012931-A1 | High specificity marker detection | THOMAS JEFFERSON UNIVERSITY | 2002-01-31 | — | — | US | claimed |
| WO-2001073131-A1 | HIGH SPECIFICITY MARKER DETECTION | THOMAS JEFFERSON UNIVERSITY (US) | 2001-10-04 | — | — | WO | claimed |
| US-5034383-A | Hypotensive agents for bone disorders | COLGATE-PALMOLIVE COMPANY (US) | 1991-07-23 | — | — | US | claimed |
| US-4975423-A | ADMINISTERING A PEROXYDIPHOSPHORIC ACID SALT OF A 1A METAL, 2A METAL, ZINC OR TIN, AN ESTER OR QUARTERNARY AMMONIUM SALT | COLGATE-PALMOLIVE COMPANY (US) | 1990-12-04 | — | — | US | claimed |
| WO-1986000225-A1 | INHIBITION OF TUMOR DEVELOPMENT | COLGATE-PALMOLIVE COMPANY (US) | 1986-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190234956-A1 | METHOD FOR DETECTING CROSSLINKED PEPTIDES VIA REPRODUCIBLE FRAGMENTATION IN A MASS SPECTROMETER | PTMS, DCLRE1A, PDAP1 | HINT1 2278/4885NT5E 3303/4885GSK3A 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.